Phase I Study To Evaluate Cellular Adoptive Immunotherapy Using Autologous CD8+ Antigen-Specific T Cell Clones Following Cyclophosphamide Conditioning For Patients With Metastatic Melanoma.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Aldesleukin; Cancer vaccine; Cyclophosphamide
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- 15 Feb 2017 Biomarkers information updated
- 21 Apr 2011 Actual trial end date (Aug 2010) added as reported by ClinicalTrials.gov.
- 21 Apr 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.